Valuation: Kymera Therapeutics, Inc.

Market Cap 9.78B 8.77B 8.1B 7.35B 13.73B 929B 13.9B 97.13B 38.58B 487B 36.7B 35.91B 1,543B P/E 2026 *
-30.3x
P/E 2027 * -23.2x
Enterprise Value 8.47B 7.61B 7.02B 6.37B 11.9B 805B 12.05B 84.19B 33.44B 422B 31.81B 31.13B 1,338B EV / Sales 2026 *
80.9x
EV / Sales 2027 * 214x
Free-Float
97.88%
Yield 2026 *
-
Yield 2027 * -
1 day+3.03%
1 week+7.49%
Current month+8.30%
1 month+8.10%
3 months+14.04%
6 months+44.39%
Current year+55.60%
1 week 109.05
Extreme 109.05
121.8
1 month 101.74
Extreme 101.745
121.8
Current year 66.2
Extreme 66.205
130.05
1 year 55.66
Extreme 55.66
130.05
3 years 9.6
Extreme 9.6
130.05
5 years 9.6
Extreme 9.6
130.05
10 years 9.6
Extreme 9.6
130.05
Manager TitleAgeSince
Chief Executive Officer 47 2019-10-31
Director of Finance/CFO 56 2019-07-14
Chief Tech/Sci/R&D Officer - 2026-07-26
Director TitleAgeSince
Chairman 52 2017-07-31
Director/Board Member 47 2019-10-31
Director/Board Member 37 2020-02-29
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Exercice

Founder

90,000 0.1082%
9/4/26 Sell

General Counsel

-6,371 0.0077%
7/27/26 Free

Chief Technology Officer

114,000 0.1386%
Change 5-day change 1-year change 3-year change Capi.($)
+3.02%+7.49%+95.43%+979.05% 9.78B
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+1.27%+11.82%+82.12% 54.55B
-0.94%+0.99%+10.45%+102.18% 53.59B
+1.73%-0.08%+26.72%+56.03% 44.75B
+2.14%-3.31%+17.93%+100.24% 41.62B
+0.24%-4.05%+220.47%+915.91% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+47.63%+107.12%+94.27% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.19%-0.01%+55.94%+243.29% 39.02B
Weighted average by Cap. +3.00%-0.19%+48.22%+180.75%

Financials

2026 *2027 *
Net sales 105M 94.03M 86.82M 78.73M 147M 9.95B 149M 1.04B 413M 5.22B 393M 385M 16.54B 40.65M 36.48M 33.69M 30.55M 57.1M 3.86B 57.8M 404M 160M 2.02B 153M 149M 6.42B
Net income -382M -343M -317M -287M -537M -36.33B -544M -3.8B -1.51B -19.04B -1.44B -1.41B -60.39B -521M -468M -432M -391M -732M -49.48B -741M -5.18B -2.06B -25.94B -1.96B -1.91B -82.25B
Net Debt -1.3B -1.17B -1.08B -979M -1.83B -124B -1.85B -12.94B -5.14B -64.83B -4.89B -4.78B -206B -1.09B -977M -902M -818M -1.53B -103B -1.55B -10.81B -4.29B -54.17B -4.08B -4B -172B
Projected Income Statement - Annual - Kymera Therapeutics, Inc.
Logo Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.
Employees
273
Date Price Change Volume
26-10-28 US$120.88 +2.81% 279,875
26-10-27 US$117.57 +2.38% 828,869
26-10-26 US$114.84 +3.68% 438,576
26-10-23 US$110.76 -0.08% 517,064
26-10-22 US$110.85 -1.58% 850,270
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Kymera Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
117.57USD
Average target price
139.83USD
Spread / Average Target
+18.93%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Kymera Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. KYMR Stock